Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 24383924)

1.

Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C.

Baran B, Gulluoglu M, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Yesil S, Akyuz F, Karaca C, Demir K, Kaymakoglu S, Besisik F.

J Viral Hepat. 2014 Feb;21(2):111-20. doi: 10.1111/jvh.12127. Epub 2013 Aug 27.

PMID:
24383924
2.

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M.

Ann Intern Med. 2000 Apr 4;132(7):517-24.

PMID:
10744587
3.

Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.

Taniguchi H, Iwasaki Y, Fujiwara A, Sakaguchi K, Moriya A, Yu PC, Takaki A, Fujioka S, Shimomura H, Shiratori Y.

J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):281-7.

PMID:
16460487
4.

Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy.

Cartón JA, Collazos J, de la Fuente B, Asensi V.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):215-22. doi: 10.1089/AID.2012.0108. Epub 2012 Jul 31.

PMID:
22734850
5.
6.

Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study.

Mirza S, Siddiqui AR, Hamid S, Umar M, Bashir S.

BMC Gastroenterol. 2012 Jun 14;12:71. doi: 10.1186/1471-230X-12-71.

7.

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.

Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG.

J Viral Hepat. 2003 Jan;10(1):16-22.

PMID:
12558907
8.
9.

Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.

Ingiliz P, Valantin MA, Preziosi P, Finzi L, Pais R, Fedchuk L, Dominguez S, Katlama C, Poynard T, Benhamou Y.

J Hepatol. 2012 Jan;56(1):49-54. doi: 10.1016/j.jhep.2011.05.028. Epub 2011 Jul 23.

PMID:
21781946
10.

Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).

Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ; HALT-C Trial group.

Pharmacogenet Genomics. 2011 Dec;21(12):851-60. doi: 10.1097/FPC.0b013e32834c3e74.

11.

Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count.

Bonnard P, Lescure FX, Amiel C, Guiard-Schmid JB, Callard P, Gharakhanian S, Pialoux G.

J Viral Hepat. 2007 Nov;14(11):806-11.

PMID:
17927617
12.

Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.

Rusu E, Jinga M, Enache G, Rusu F, Dragomir AD, Ancuta I, Draguţ R, Parpala C, Nan R, Sima I, Ateia S, Stoica V, Cheţa DM, Radulian G.

Nutr J. 2013 Aug 14;12:119. doi: 10.1186/1475-2891-12-119.

13.

Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.

Hissar SS, Kumar M, Tyagi P, Goyal A, Suneetha PV, Agarwal S, Rastogi A, Sakhuja P, Sarin SK.

J Gastroenterol Hepatol. 2009 Apr;24(4):581-7. doi: 10.1111/j.1440-1746.2008.05649.x. Epub 2008 Nov 20.

PMID:
19032460
14.

Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study.

Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, Marxuach-Cuétara AM, López-Torres A, Jiménez-Rivera J.

J Hepatol. 2007 Apr;46(4):613-9. Epub 2007 Jan 26.

PMID:
17316873
15.

Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Aug;137(2):549-57. doi: 10.1053/j.gastro.2009.05.007. Epub 2009 May 13.

16.

Progression of fibrosis in chronic hepatitis C.

Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH.

Gastroenterology. 2003 Jan;124(1):97-104.

PMID:
12512034
17.

Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.

Hung CH, Kuo FY, Wang JH, Lu SN, Hu TH, Chen CH, Lee CM, Eng HL.

Antivir Ther. 2006;11(4):483-9.

PMID:
16856622
18.

Clinical, virologic and pathologic significance of elevated serum gamma-glutamyl transpeptidase in patients with chronic hepatitis C.

Hwang SJ, Luo JC, Lai CR, Chu CW, Tsay SH, Lu CL, Wu JC, Chang FY, Lee SD.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 Jul;63(7):527-35.

PMID:
10934805
19.

Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?

Vardar R, Vardar E, Demiri S, Sayhan SE, Bayol U, Yildiz C, Postaci H.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1459-65.

PMID:
19950810
20.

Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.

Mendoza J, Trapero-Marugán M, González-Moreno L, Jones EA, Gómez-Domínguez E, Moreno-Otero R.

Rev Esp Enferm Dig. 2010 Jul;102(7):426-34.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk